Clarametyx Biosciences, a Columbus, OH-based clinical stage company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms, raised $33M in Series A funding.
The round was led by Ohio Innovation Fund, with participation from current investors Nationwide Children’s Hospital, Rev1 Ventures, JobsOhio Growth Capital, C Bio Investors and 1776 Fund.
The company intends to use the funds to accelerate efforts across its pipeline, including specifically to evaluate the potential of its lead therapeutic candidate CMTX-101 to combat infection in people with cystic fibrosis (CF), a progressive, genetic disease that affects the lungs, pancreas and other organs.
Led by CEO David Richards, Clarametyx Biosciences is combating the challenge of persistent and recalcitrant infections through a technology platform targeting the biofilm—a protective layer around bacteria—to enable a more effective immune response and antibiotic intervention. The company is building a dynamic pipeline of immune-enabling therapies and vaccines for life-threatening bacterial infections associated with biofilms, with a near-term focus on challenging respiratory infections.
In coordination with the fundraising, Clarametyx has initiated a Phase 1b/2a clinical trial evaluating its lead candidate, CMTX-101, in people with CF. This study will evaluate the safety and tolerability, PK, immunogenicity, reduction of pulmonary P. aeruginosa burden, and exploratory endpoints of CMTX-101 as an adjunct therapy to standard of care antibiotics in people with CF.
FinSMEs
06/01/2024